Welcome to the newsletter from LUNGevity's Rare Mutations & Fusions Patient Gateway.
Summer may be winding down, but the pace of scientific progress in treating lung cancer driven by rare mutations and fusions shows no signs of slowing. In this issue, we are pleased to share advances in the development of drugs to target ROS1+ and RET+ non-small cell lung cancer (NSCLC). This progress is a testament to recent advances fueled by lung cancer research.
While we also know the importance of patients' receiving comprehensive biomarker testing when newly diagnosed or at progression, we are also witnessing a growing focus on biomarker testing in early-stage disease. Matching patients to the right treatment for their particular type of lung cancer is critical for ensuring optimal outcomes, and we can expect to see increased calls to implement testing earlier in the years ahead.
Research News
PharmaShots
BMS Reports P-I/II Study (TRIDENT-1) Results of Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published Aug 17, 2023
ONS Voice
FDA Approves Pralsetinib for Non-Small Cell Lung Cancer With RET Gene Fusions
Published Aug 10, 2023
OncLive
Selpercatinib Meets PFS End Point in Newly Diagnosed Advanced or Metastatic RET+ NSCLC
Published Aug 4, 2023
OncLive
Routine Molecular Testing in Early NSCLC Post-Resection
Published Jul 24, 2023
Get Connected
Join us for the Rare Mutations & Fusions Virtual Meetup
It’s the easy way to build your community. The first Wednesday of each month, you can connect with others who understand what it’s like to live with lung cancer that is driven by rare mutations and fusions. The next Rare Mutations & Fusions Virtual Meetup is happening on Wednesday, October 4, 2023, at 3 pm ET. Register for the Rare Mutations & Fusions Meetup to get a confirmation email with details about how to join the virtual meeting.
Register for the ILCSC (September 22-23,
2023)
The International Lung Cancer Survivorship Conference is LUNGevity’s annual conference (held virtually) to inform patients and caregivers about the latest lung cancer research and treatments. The popular session dedicated to rare mutations in lung cancer is back again this year. Learn more about this free conference and the world-renowned researchers who will be speaking.
Have You Seen?
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. This article discusses some of the work being done to decentralize clinical trials and improve access for patients. Read it here.
Emotional Care for the Whole Family
A diagnosis of cancer has an impact on the entire family. Emotional support from family and friends can make a significant difference to the experience of survivorship, but knowing when, how, and in what way to offer support can be a challenge to figure out. In this article, Julie Larson, a licensed clinical social worker, offers guidance on these challenging situations. Read it here.
Shared Decision-Making, Self-Advocacy, and Dealing with Financial Toxicity
In this webinar, oncologist Cardinale Smith, MD, PhD, discusses how it is possible and preferable for the healthcare team to make treatment decisions that align with the patient’s goals. Watch it here.
…and so much more at the Rare Mutations & Fusions Patient Gateway.
If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here.
If you need further assistance along your lung cancer journey, please email us at support@lungevity.org. Our team is always here to assist you.
